Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH

05-06-2021 | ASCO 2021 | Conference coverage | Video

Sotorasib continues to show potential in KRAS-mutant NSCLC

Ferdinandos Skoulidis presents an update from the CodeBreaK 100 trial of sotorasib in previously treated patients with non-small-cell lung cancer and KRAS G12C mutations, focusing on overall survival data and a subgroup analysis by co-mutations (3:58).

External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.

Read transcript

Related content

29-01-2021 | Non-small-cell lung cancer | News

CodeBreaK 100 update confirms sotorasib efficacy in KRAS-mutated NSCLC

03-06-2021 | FDA | News

Sotorasib approved for KRAS-mutated NSCLC in USA

13-04-2021 | AACR 2021 | Conference coverage | News

Mechanisms of resistance to KRAS G12C inhibition characterized

29-03-2021 | Non-small-cell lung cancer | News

Novel KRAS inhibitor adagrasib findings reported for advanced NSCLC
Image Credits